Moderate hyperprolactinemia is associated with survival in patients with acute graft-versus-host disease after allogeneic stem cell transplantation

References

• Thomas ED. Hematopoietic stem cell transplantation. Sci Am. 1995;272:38–47.
   Google Scholar
• Reddy P. Pathophysiology of acute graft-versus-host disease. Hematol Oncol. 2003;21:149–61.
   PubMed Web of Science ®Google Scholar
• Lunn RA, Sumar N, Bansal AS, Treleaven J. Cytokine profiles in stem cell transplantation: possible use as a predictor of graft-versus-host disease. Hematology. 2005;10:107–14.
   PubMed Web of Science ®Google Scholar
• Krenger W, Ferrara JL. Graft-versus-host disease and the Th1/Th2 paradigm. Immunol Res. 1996;15:50–73.
   PubMed Web of Science ®Google Scholar
• Hinterberger-Fischer M, Kier P, Spona J, Sebesta C, Tiefengraber E, Habertheuer KH, et al. Prolactin: a possible mediator of graft-versus-host disease following allogeneic bone marrow transplantation in humans. Bone Marrow Transplant. 1994;14:403–6.
   PubMed Web of Science ®Google Scholar
• Matera L. Action of pituitary and lymphocyte prolactin. Neuroimmunomodulation. 1997;4:171–80.
   PubMed Web of Science ®Google Scholar
• Matera L, Mori M. Cooperation of pituitary hormone prolactin with interleukin-2 and interleukin-12 on production of interferon-gamma by natural killer and T cells. Ann NY Acad Sci. 2000;917:505–13.
   PubMed Web of Science ®Google Scholar
• Richards SM, Murphy WJ. Use of human prolactin as a therapeutic protein to potentiate immunohematopoietic function. J Neuroimmunol. 2000;109:56–62.
   PubMed Web of Science ®Google Scholar
• Welniak LA, Richards SM, Murphy WJ. Effects of prolactin on hematopoiesis. Lupus. 2001;10:700–5.
   PubMed Web of Science ®Google Scholar
• Sun R, Gault RA, Welniak LA, Tian ZG, Richards S, Murphy WJ. Immunologic and hematopoietic effects of recombinant human prolactin after syngeneic bone marrow transplantation in mice. Biol Blood Marrow Transplant. 2003;9:426–34.
   PubMed Web of Science ®Google Scholar
• Sun R, Zhang J, Zhang C, Zhang I, Liang S, Sun A, et al. Human prolactin improves engraftment and reconstitution of human peripheral blood lymphocytes in SCID mice. Cell Mol Biol. 2004;1:129–36.
   Web of Science ®Google Scholar
• Matera L. Endocrine, paracrine and autocrine actions of prolactin on immune cells. Life Sci. 1996;59:599–614.
   PubMed Web of Science ®Google Scholar
• Chuang E, Molitch ME. Prolactin and autoimmune diseases in humans. Acta Biomed. 2007;78 (Suppl. 1):255–61.
   PubMedGoogle Scholar
• Reber PM. Prolactin and immunomodulation. Am J Med. 1993;95:637–44.
   PubMed Web of Science ®Google Scholar
• Ben-Jonathan N. Dopamine: a prolactin inhibiting hormone. Endocr Rev. 1985;6:564–89.
   PubMed Web of Science ®Google Scholar
• Quigley ME, Judd SJ, Gilliland GB, Yen SSC. Effects of a dopamine antagonist on the release of gonadotropin and prolactin in normal women and in women with hyperprolactinemic anovulation. J Clin Endocrinol Metab. 1979;98:718–20.
   Google Scholar
• Parra A, Ramírez-Peredo J, Larrea F, Cabrera V, Coutiño B, Torres I, et al. Decreased dopaminergic tone and increased basal bioactive prolactin in men with immunodeficiency virus infection. Clin Endocrinol (Oxf). 2001;54:731–8.
   PubMed Web of Science ®Google Scholar
• Parra A, Ramírez-Peredo J, Hidalgo R, Morales-Toquero A, Velásquez-Ramírez G, Ruiz-Argüelles A, et al. Altered functional status of the hypothalamic dopaminergic tone in patients with chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: a pilot study. Biol Blood Marrow Transplant. 2006;12:566–72.
   PubMed Web of Science ®Google Scholar
• Yen SSC. Prolactin in human reproduction. In: , Yen SSC, Jaffe RB, (eds.) Reproductive endocrinology. 3rd ed. Philadelphia: Saunders; 1991. p. 357–88.
   Google Scholar
• Kessinger A, Armitage JO, Landmark JD, Smith DM, Weisenburger DD. Autologous peripheral hematopoietic stem cell transplantation restores hemopoietic function following marrow ablative therapy. Blood. 1998;71:723–7.
   Google Scholar
• Ruiz-Argüelles A. Flow cytometry in the clinical laboratory. Principles, applications and problems. Ann Biol Clin. 1992;50:735–43.
   PubMed Web of Science ®Google Scholar
• Ruiz-Argüelles A, Orfao A. Caracterización y evaluación de células totipotenciales en sangre periférica y médula ósea. In: , Ruiz-Argüelles GJ, San-Miguel JF, (eds.) Actualización en Leucemias. 1st ed. México City: Editorial Médica Panamericana; 1996. p. 79–82.
   Google Scholar
• Ruiz-Argüelles GJ, Gómez-Almaguer D, López-Martínez B, Cantú-Rodríguez OG, Jaime-Pérez JC, González-Llano O. Results of an allogeneic non-myeloablative stem cell transplantation program in patients with chronic myelogenous leukemia. Haematologica. 2002;87:894–6.
   PubMed Web of Science ®Google Scholar
• Ruiz-Argüelles GJ, Gómez-Almaguer D, Morales-Toquero A, Gutiérrez-Aguirre CH, Vela-Ojeda J, García-Ruiz-Esparza MA, et al. Latin American Cooperative Oncohematology Group. The early referral for reduced-intensity stem cell transplantation in patients with Ph1 (+) chronic myelogenous leukemia in chronic phase in the imatinib era: results of the Latin American Cooperative Oncohematology Group (LACOHG) prospective, multicenter study. Bone Marrow Transplant. 2005;36:1043–7.
   PubMed Web of Science ®Google Scholar
• Pinkel D, Straume T, Gray JW. Cytogenetic analysis using quantitative, high sensitivity fluorescence hybridization. Proc Natl Acad Sci USA. 1996;83:2934–8.
   Web of Science ®Google Scholar
• Yam P, Petz L, Knowlton R, Wallace R, Stock A, deLange G, et al. Use of DNA restriction fragment length polymorphisms to document marrow engraftment and mixed hematopoietic chimerism following bone marrow transplantation. Transplantation. 1987;43:399–407.
   PubMed Web of Science ®Google Scholar
• Tai MM. A mathematical model for the determination of total area under glucose tolerance and oter metabolic curves. Diabetes Care. 1994;17:152–4.
   PubMed Web of Science ®Google Scholar
• Suginami H, Hamada K, Yano K, Kurada G, Matsuura S. Ovulation induction with bromocriptine in normoprolactinemic anovulatory women. J Clin Endocrinol Metab. 1996;62:899–903.
   Google Scholar
• Reinthaller A, Neunteufel W, Bieglmayer C, Fischl F. The metoclopramide-provocation test for prediction of transient hyperprolactinemia during cycle stimulation. Fertil Steril. 1990;53:368–71.
   PubMed Web of Science ®Google Scholar
• Kast R. Blocking of cyclosporine immunosupression by neuroleptics. Transplantation. 1989;47:1095–6.
   PubMed Web of Science ®Google Scholar
• Clevenger CV, Freier DO, Kline JB. Prolactin receptor signal transduction in cells of the immune system. J Endocrinol. 1998;157:187–97.
   PubMed Web of Science ®Google Scholar
• Gala RR. The physiology and mechanisms of stress-induced changes in prolactin secretion in the rat. Life Sci. 1990;46:1407–20.
   PubMed Web of Science ®Google Scholar
• Kant GJ, Bauman RA, Anderson SM, Mongey EH. Effects of controllable and uncontrollable chronic stress on stress-responsive plasma hormones. Physiol Behav. 1992;51:1285–8.
   PubMed Web of Science ®Google Scholar
• Weimann E, Baixeras E, Zamzani M, Kelly P. Prolactin blocks glucocorticoid-induced cell death by inhibiting the disruption of the mitocondrial membrane. Leuk Res. 1999;23:751–62.
   PubMed Web of Science ®Google Scholar
• Parra A, Ramírez-Peredo J, Larrea F, Pérez-Romano B, Cabrera V, Torres I, et al. Serum prolactin is associated with apoptosis in men with immunodeficiency virus infection. Immunol Cell Biol. 2001;79:285–90.
   PubMed Web of Science ®Google Scholar
• Leff MA, Buckley DJ, Krumenacker JS, Reed JC, Miyashita T, Buckley AR. Rapid modulation of the apoptosis regulatory genes, bcl-2 and bax by prolactin in rat Nb2 lymphoma cells. Endocrinology. 1996;137:5456–62.
   PubMed Web of Science ®Google Scholar
• Krumenacker JS, Buckley DJ, Leff MA, Mc Cormack JT, De Jong G, Gout PW, et al. Prolactin regulated apoptosis of Nb2 lymphoma cells: pim-1, bcl-2, and bax expression. Endocrine. 1998;9:163–70.
   PubMed Web of Science ®Google Scholar
• Parra A, Reyes-Terán G, Ramírez-Peredo J, Benedict J, Quiroz V, Cárdenas M, et al. Differences in nocturnal basal and rhythmic prolactin secretion in untreated compared to treated HIV-infected men are associated with CD4+ T-lymphocytes. Immunol Cell Biol. 2004;82:24–31.
   PubMed Web of Science ®Google Scholar
• Clevenger CV, Rusell DA, Appasamy PM, Pristowsky MB. Regulation of interleukin-2-driven T-lymphocyte proliferation by prolactin. Proc Natl Acad Sci USA. 1990;87:6460–4.
   PubMed Web of Science ®Google Scholar
• Clevenger CV, Sillman AL, Hanley-Hyde J, Pristowsky MB. Requirement for prolactin during cycle regulated gene expression in cloned T-lymphocytes. Endocrinology. 1992;130:3216–22.
   PubMed Web of Science ®Google Scholar
• Matera L, Cesano A, Bellone G, Oberholtzer E. Modulatory effect of prolactin on the resting and mitogen-induced activity of T, B, and NK lymphocytes. Brain Behav Immun. 1992;6:409–17.
   PubMed Web of Science ®Google Scholar
• Fowler DH, Gress RE. Th2 and Tc cells in the regulation of GVHD, GVL, and graft rejection: considerations for the allogeneic transplantation therapy of leukemia and lymphoma. Leuk Lymphoma. 2000;38:221–34.
   PubMed Web of Science ®Google Scholar
• Mariotti J, Foley J, Ryan K, Buxhoeveden N, Kapoor V, Amarnath S, et al. Graft rejection as a Th1-type process amenable to regulation by donor Th2-type cells through an interleukin-4/STAT6 pathway. Blood. 2008;112:4765–75.
   PubMed Web of Science ®Google Scholar
• Hinterberger-Fisher M, Hinterberger W. Blood stem cell transplantation for breast cancer: new approaches using pre-peri-post transplant immunotherapy. Expert Opin Biol Ther. 2001;1:1029–48.
   PubMed Web of Science ®Google Scholar
• Hernández-Ruiz J, Farfán B, Córdoba J, Parra A, Ramírez J, Kershenobich D, et al. Effect of prolactin in-vitro and in-vivo on perforin and trail expression in human NK lymphocytes. Eur J Immunol. 2009;39 (Suppl. 1):S-345.
   Google Scholar